180 Life Sciences’ Woody Sets Out Vision For Repurposing Anti-TNF Biologics

CEO Expands On Recent Announcement Of Collaboration With Celltrion

After 180 Life Sciences recently struck a deal with Korea’s Celltrion to support its work in repurposing off-patent biologics, CEO Jim Woody speaks to Generics Bulletin about what the collaboration means for the company and its next steps.

Three Targets Arrows
Three new indications are being targeted by the company • Source: Alamy

California-based biotech firm 180 Life Sciences recently took a step forward with its plans to develop repurposed off-patent biologics, striking a deal with Korea’s Celltrion “for the ongoing supply of drugs for anti-TNF product trials for novel indications.”

Following the announcement, 180 Life Sciences CEO Jim Woody spoke to Generics Bulletin about how the collaboration would support the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business